FOCUS
We want to see if a new antipsychotic drug called xanomeline-trospium can help to treat psychosis, as well as problems with thinking, memory, and concentration.
People who have psychosis are usually given treatment to help them feel better. These drugs are called antipsychotics. They can be helpful for some patients, but less so for others. The patients who don’t find them helpful often want to change to another treatment to help them feel better. Many people with psychosis have problems with things like concentration, memory, learning, and day to day activities; we call these 'cognitive problems', or 'cognitive deficits'.
Who are we looking for?
We are looking for people aged between 18 and 55 with psychosis OR people without psychosis, known as 'Healthy Controls'.
For more information, and to see whether you may be eligible to take part, please download the relevant Participant Information Sheet, below:
Trial status: In set-up. Recruitment opening May 2026.
Contact Details: focus@psych.ox.ac.uk
Protocol: 1010141 V6.0/20Feb2026
ISRCTN Number: 59554792
Trial Recruitment Timeline: May 2026 - March 2032.
REC: 25/SW/0096
Recruiting Sites
Investigators
Professor Oliver Howes - Principal Investigator at our South London and Maudsley NHS Foundation Trust Site.
Dr Ellice Caldwell-Dunn - King's College London, Clinical Researcher
Professor Belinda Lennox - University of Oxford
Professor Philip McGuire - University of Oxford
Dr Thomas Kabir - University of Oxford
Dr Bodyl Brand - University of Oxford
Dr Sameer Jauhar - Imperial College London
Professor Paolo Fusar-Poli - King's College London
Lucy Cureton - University of Oxford
Relevant Publications
Psychosis as a disorder of muscarinic signalling: psychopathology and pharmacology McCutcheon et. al., (2024)
Xanomeline/trospium chloride in schizophrenia: a profile of its use McGuigan, A., Blair, H.A, (2025).
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia. A Randomized Clinical Trial. Kaul et al., (2024).
Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia Ramey, O. L., & Silva Almodóvar, A. (2025).
